XL999 Administered Intravenously to a Subject With Advanced Malignancies
Status:
No longer available
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Cancer is a worldwide clinical and economic problem. Conventional approaches to treating
cancer include surgery, radiotherapy, and cytotoxic chemotherapy as single modalities or as
combined therapies. Recently, targeted therapies including antibodies and small molecule
inhibitors have also demonstrated clinical benefit. It is now possible to study different
genetic lesions involved in cancer types due to advances in genomic methodologies. The
investigational drug in this study, XL999 inhibits multiple receptor tyrosine kinases,
including VEGF receptor (VEGFR2/KDR), platelet derived growth factor receptors (PDGFRβ),
fms-like tyrosine kinase receptor 3 (FLT3), fibroblast growth factor receptors (FGFR1,
FGFR3), RET, and KIT, and thus, interferes with multiple cellular processes simultaneously
and will likely have effects on the integrity of tumor neovasculature and angiogenesis.
Together with the ability to induce a novel cell cycle arrest, the spectrum of activities
that XL999 exhibits may reduce both tumor cell proliferation and angiogenesis in the clinic.
The rationale and purpose of this maintenance study is to allow a subject receiving clinical
benefit from XL999 to continue treatment.